https://pharmatlas.org/ 2026-04-06T09:29:42+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-15T15:09:28+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:antimuscarinics&rev=1771168168&do=diff Antimuscarinics (SAMA / LAMA) Antimuscarinics bronchodilate by blocking vagal bronchoconstriction rather than stimulating dilation. They are the foundation maintenance bronchodilators in COPD and adjunct therapy in asthma. These medications are a respiratory application of text/html 2026-02-15T15:05:44+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:beta2_agonists&rev=1771167944&do=diff β2-Agonists (SABA / LABA) β2-agonists relax bronchial smooth muscle and are the primary bronchodilators used in obstructive lung disease. They do NOT treat inflammation — they only open the airway. SABA = rescue (fast relief) LABA = maintenance (prevention) text/html 2026-02-15T14:33:51+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:start&rev=1771166031&do=diff Respiratory Pharmacology Respiratory diseases fall into two fundamentally different categories: * AIRWAY PROBLEM → obstruction & bronchospasm → bronchodilators + inhaled anti-inflammatories * * PARENCHYMAL PROBLEM → alveolar injury & fibrosis → antifibrotics & immunosuppression